Immunotherapy of Stage III/IV Melanoma Patients

Summary

The purpose of this study is to determine whether vaccination with melanoma antigen peptides \[Melan-A/Mart-1 (both EAA and ELA), NY-ESO-1b analog, Long NY-ESO-1 LP and MAGE-A10\] and Montanide, CpG adjuvants and low dose rIL-2 can induce an immune response in melanoma patients and to assess the safety of this vaccination.

Conditions

• Melanoma

Interventions

BIOLOGICAL

Melan-A ELA + Montanide

A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received "booster vaccinations" every 3 months.

BIOLOGICAL

Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide

A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received "booster vaccinations" every 3 months.

BIOLOGICAL

Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG

A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received "booster vaccinations" every 3 months.

BIOLOGICAL

Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG

A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received "booster vaccinations" every 3 months.

BIOLOGICAL

Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2

A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received "booster vaccinations" every 3 months.

Sponsors & Collaborators

• Ludwig Institute for Cancer Research

  collaborator OTHER

• Centre Hospitalier Universitaire Vaudois

  lead OTHER

Principal Investigators

• Olivier Michielin, MD PhD · Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois)

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2004-02-29

Primary Completion

2013-03-31

Completion

2013-03-31

Countries

• Switzerland

Study Locations